Compare QMCO & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QMCO | RNA |
|---|---|---|
| Founded | 1980 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.1M | 141.3M |
| IPO Year | 2025 | 2025 |
| Metric | QMCO | RNA |
|---|---|---|
| Price | $17.00 | $8.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $27.33 | $22.00 |
| AVG Volume (30 Days) | ★ 1.5M | 212.2K |
| Earning Date | 11-09-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.34 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $372,827,000.00 | N/A |
| Revenue This Year | $20.02 | $88.07 |
| Revenue Next Year | $16.01 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 6.65 | N/A |
| 52 Week Low | $4.19 | $7.49 |
| 52 Week High | $35.65 | $73.06 |
| Indicator | QMCO | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 41.04 | 46.75 |
| Support Level | $16.74 | $7.56 |
| Resistance Level | $18.48 | $8.50 |
| Average True Range (ATR) | 1.70 | 0.36 |
| MACD | -0.25 | 0.12 |
| Stochastic Oscillator | 51.18 | 47.93 |
Quantum Corp is a United States-based company that delivers end-to-end data management solutions designed for unstructured data in the era of artificial intelligence (AI). It provides one of the comprehensive and cost-efficient solutions for the entire data lifecycle. The group provides solutions for video, images, audio, and other large files because this unstructured data represents. Its portfolio of products includes primary storage software and systems, secondary storage software and systems, as well as devices and media. The group operates in three geographic regions: Americas, Europe, the Middle East, and Africa (EMEA), and Asia Pacific (APAC).
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.